Thrombolytic therapy significantly improves the natural history of acute myocardial infarction, but recent data suggest that current reperfusion strategies have yet to realize the maximum potential for reduction of mortality and salvage of ventricular function. Coronary patency rates as high as 85% assessed by angiography 90 minutes after initiation of treatment greatly overestimate the efficacy of thrombolytic regimens, as this conventional angiographic "snapshot" view does not satisfactorily reflect the dynamic processes of coronary artery recanalization and reocclusion or the adequacy of myocardial perfusion. In
Erratum
This article, which originally appeared on page 1792 of the June 1993 issue of Circulation, was mistakenly printed with figures from another article. The printer has agreed to reprint the article in its entirety. Th hrombolytic therapy has been unequivocally demonstrated to markedly improve the natural history of acute myocardial infarction, with an approximate 30% reduction in mortality in randomized, controlled trials1-5 and more modest recovery of global or infarct-zone left ventricular function.5-9 In the decade since the introduction of thrombolytic agents for the management of infarction, substantial progress has been made in increasing acute patency rates,10 11 optimizing dosage regimens, recognizing the critical importance of coadministered antiplatelet agents,2 and expanding patient selection criteria. These achievements, coupled with the seemingly paradoxical lack of apparent clinical benefit from more aggressive approaches with newer thrombolytic agents12'13 or routine, adjunctive mechanical infarct vessel revascularization,14-'7 have led to a degree of complacency regarding the effectiveness of current myocardial reperfusion therapy.
Illusion of Reperfusion
Substantial recent data, however, suggest that thrombolytic strategies have yet to realize the maximum potential for reduction of mortality and salvage of ventricular function after acute myocardial infarction. Although an impressive proportion of patients are found to have "patent" infarct arteries after thrombolysis, this conventional assessment of efficacy in terms of an angiographic "snapshot" view does not satisfactorily reflect the dynamic processes of coronary arterial recanalization and reocclusion or the adequacy of myocardial perfusion. Newer technologies, such as contrast perfusion echocardiography and continuous 12-lead digital ECG, have enhanced detection of the stability and true extent of reperfusion. The purpose of this review is to provide a critical, contemporary evaluation of the efficacy of thrombolytic therapy, with consideration of each of the key components of "optimal reperfusion": rapid, complete, and sustained restoration of perfusion to the myocardium subserved by an infarctrelated artery.
'Patency' Is Not Equal to 'Reperfusion' Contributing to the overly optimistic view of the effectiveness of current thrombolytic therapy is a tendency to equate the various terms used to describe the state of the infarct-related artery after administration of these agents. These terms, as strictly defined, are not interchangeable. "Patency" denotes the proportion of infarct arteries that are found to be unoccluded at the time of coronary angiography and consequently encompasses those vessels that never were totally occluded at baseline, those that spontaneously achieved patency, and those that were acted on successfully by fibrinolytic agents. "Recanalization," a more rigorous measure than patency of the effectiveness of treatment, refers to those infarct arteries that were demonstrated to be occluded at baseline and subsequently become patent with therapy. "Reflow" (for this discussion, at least) may be considered to represent the quality and briskness of blood flow in the epicardial artery beyond a patent stenosis. Finally, "reperfusion" may be seen as representing the ultimate goal and most pertinent end point of thrombolytic therapy: the reestablishment of tissue-level perfusion within the jeopardized myocardium. The dissociation that may exist between epicardial artery patency and myocardial tissue reperfusion has only recently become evident, and the exclusive angiographic end point addressed by nearly all previous clinical trials has been infarct vessel patency.
Restoration of Infarct Artery Patency
Although a few investigators have argued that the salutary effects of thrombolytic agents may result from mechanisms other than restoration of infarct artery patency,18 it is almost universally accepted that benefit with this form of therapy is linked to the establishment of an open artery. Failed recanalization after thrombolysis has been associated with higher rates of in-hospital mortality and morbidity and with minimal recovery of left ventricular function compared with outcome in patients in whom reperfusion is successful.1920 Longterm prognosis also appears to be substantially improved among patients with an open artery compared with those who fail reperfusion therapy,21-23 although a major caveat in interpreting these data has been the possibility that patients with successful restoration of patency may in some way represent a healthier cohort destined to have a better prognosis.
During the first 24 hours after acute myocardial infarction, angiography reveals a patent infarct-related artery in only 9-29% of patients who have not been treated with reperfusion therapy.24-28 Thus, conventional angiographic assessment of the efficacy of various thrombolytic agents has focused on the establishment of infarct artery patency, typically at 90 minutes after initiation of therapy. By this criteria, early effective thrombolysis is achieved least frequently after treatment with intravenous streptokinase (43-64%) 26 The "catch-up" phenomenon of infarct vessel patency with streptokinase and other nonfibrin-specific plasminogen activators renders angiographic differences between the thrombolytic agents less distinct after 2-3 hours, although at least 10-15% of patients will ultimately fail to achieve recanalization of the infarctrelated artery, regardless of the thrombolytic regimen. The pathophysiological basis for the ineffectiveness of thrombolysis in some patients appears to be multifactorial. The relative proportions of platelet-rich and erythrocyte-rich zones in the occlusive thrombotic mass may be influenced by the depth of arterial plaque fissuring and wall injury,44"45 with platelet-rich thrombi exhibiting intrinsic resistance to clot lysis.46 Extrinsic luminal compression from plaque hemorrhage or extensive rupture, which has been referred to as "plaque disaster,"47 also may prevent pharmacological coronary recanalization on a mechanical basis. Beyond these differences in the constitution of the occlusive thrombus or underlying lesion, the antigenicity of streptokinase or anistreplase may limit the effectiveness of these agents,48 intrinsic fibrinolytic activity and that of plasminogen activator inhibitor-1 (PAI-1) vary among patients,49 and there appears to be substantial interindividual variability in fibrinogenolytic response to thrombolytic therapy.50 Finally, the currently available thrombolytic agents may be inadequately potent at maximal safe dosages and rates of administration.
Although patency rates appear to be acceptably high at 90 minutes after initiation of thrombolytic therapy, this parameter may not be an adequate reflection of optimal reperfusion. The clinical importance of rapidity of infarct artery recanalization remains a topic of considerable interest and controversy. The failure of large randomized trials to demonstrate clinical superiority of agents (t-PA and anistreplase) with greater rapidity of recanalization than streptokinase (although equivalent later patency rates) has led some to speculate that ultimate coronary patency, regardless of timing, may be the most important benefit of thrombolysis. 59 patients treated within 2 hours experienced no 60-day mortality, whereas the death rate among patients receiving rt-PA between 2-4 hours of symptom onset was 6.3% (p=0.01). In a fourth study, global and regional left ventricular ejection fractions were found to be markedly improved by very early (<1.5 hours) treatment with streptokinase,60 in comparison to the lesser degree of myocardial salvage among patients undergoing thrombolysis between 1.5 and 4 hours.
It is also noteworthy that mortality rates in the control groups of patients enrolled during the first hour of symptoms in the large-scale thrombolytic trials were higher than those for patients treated after 6 hours (15.4% versus 13 .9% in GISSI-1 and 13.4% versus 12.1% in ISIS-2 among patients presenting at <1 hour and >6 hours, respectively).12 Such early entry may have been prompted by more severe chest pain, pulmonary edema, or hemodynamic compromise and is a topic that warrants further clarification. It is conceivable, then, that patients presenting within the first hour of infarction are different from those presenting later, not only as a result of a shorter duration of ongoing myocardial necrosis and less mature thrombus at the arterial level but also prognostically. If this early-entry cohort of patients is at elevated baseline risk for mortality, the potential for risk reduction with thrombolysis may be expected to be greatest in this group.
From these data, which have led to the concept of a "golden first hour" during which initiation of thrombolytic therapy is most likely to result in mortality reduction and myocardial salvage (Figure 1 ), it may be inferred that a great rapidity of infarct artery recanalization would also confer a substantial benefit in terms of survival and preservation of ventricular function. Therefore, optimal reperfusion constitutes the establishment of angiographic patency as quickly as possible after administration of thrombolytic agents. Ideally, infarct artery recanalization would occur within 30 The ultimate goal of optimal thrombolysis is salvage of jeopardized myocardium by restoration of perfusion at the tissue level. The recent development of myocardial contrast echocardiography, a technique in which microbubbles are injected into the coronary circulation and perfusion of the subserved myocardium is assessed by two-dimensional surface echocardiography, has allowed investigation of the microcirculatory changes in ischemic myocardium. In a provocative report, Ito et a169 described 39 patients with acute anterior myocardial infarction in whom recanalization was achieved by direct coronary angioplasty or thrombolysis. Contrast echocardiography demonstrated absence of myocardial reflow, despite a patent infarct artery, in 23% of these patients; patients without microcirculatory reflow had significantly less recovery of global or regional left ventricular function than did those in whom myocardial perfusion had been restored. The authors speculated that residual perfusion defects may be a consequence of extensive myocardial necrosis and microcirculatory damage. These data suggest that the epicardial coronary artery status as determined by angiography may be dissociated from the adequacy of myocardial tissue perfusion, and the absence of reperfusion in .20% of patients with acute infarction appears to portend poor functional recovery of jeopardized myocardium.
Intermittent Coronary Patency
Oscillatory reflow and occlusion after experimental coronary thrombosis and recanalization in animal models have been described70-72; this phenomenon appears to be due primarily to obstructive aggregation of platelets at a site of vascular endothelial disruption, followed by dislodgement and embolization (Figure 2A) . Throm Figure 2B) . In a small series by Kwon et al,78 recurrence of ST segment elevation on continuous ECG monitoring during the 12 hours after acute infarction was associated with a 27% rate of reocclusion by follow-up angiography compared with 0% reocclusion in the patients who did not exhibit recurrent ST segment elevation. Reocclusion occurred in all of the patients with intermittent patency by angiography as described by Grines et al. 65 Lactate dehydrogenase (LDH) levels were significantly higher among the 34% of patients with a "highly variable ST vector magnitude" pattern on dynamic ST segment monitoring after t-PA treatment in the series by Dellborg et al,77 with a trend toward higher 1-year mortality as well (24% versus 9%, p=0.08). Thus, although the clinical significance of cyclical coronary flow after thrombolytic reperfusion remains to be clearly defined, this finding in nearly one third of patients may be associated with reduced myocardial salvage and poor long-term coronary patency. Reocclusion
Although early and complete restoration of coronary patency may result in substantial salvage of myocardium during acute infarction, this initial benefit may be attenuated by subsequent occurrence of reocclusion. Experimental coronary reocclusion in animals negates the preservation of ventricular function achieved by reperfusion79; the clinical consequences of reocclusion in humans depend on the extent of initial salvage of jeopardized myocardium and the adequacy of collateral coronary flow. Among 91 patients with reocclusion documented angiographically 0.5-38 days after successful thrombolysis (with or without adjunctive angioplasty) in the TAMI trials,80 reocclusion was associated with a greater in-hospital mortality (11.0% versus 4.5%, p=0.001), less recovery of global or infarct-zone left ventricular function, and higher rates of pulmonary edema, hypotension, respiratory failure, and atrioventricular block than was sustained infarct artery patency. Although a few small series have suggested that the risk of reocclusion may be increased by the presence of intermittent coronary patency,65 TIMI Because accelerated dosages of t-PA have been shown to produce the highest early infarct artery patency rates of all of the thrombolytic regimens, the incidence of reocclusion with this drug used in the most favorable manner is most pertinent to the consideration of optimal reperfusion. In five published studies in which t-PA was used in conjunction with both aspirin and intravenous heparin,10,26,33,34,39 the mean reocclusion rate among more than 500 patients was 13% (range, 10-20%). Combination of t-PA with a nonfibrin-selective thrombolytic agent holds promise as a means of reducing reocclusion after successful reperfusion; the reocclusion rate was 3% among 102 patients in the KAMIT As defined by its key elements of rapid, complete, and sustained coronary recanalization with adequate myocardial tissue perfusion, "optimal reperfusion" is achieved in only a small subset of patients treated with thrombolytic agents. Figure 3 illustrates the diminishing proportion of patients in whom each of the critical criteria for optimal reperfusion is successively met. Although coronary patency may be achieved in 85% of patients by 90 
Reocclusion 25% FIGURE 3. Anticipated diminishing proportion of patients successively meeting each of the criteria for optimal reperfusion after treatment for acute myocardial infarction with an accelerated regimen of tissue-type plasminogen activator. Although individual outcomes are treated as independent in this schematic, there probably is some degree of interaction between outcomes, such as TIMI grade 2 flow and reocclusion, although the magnitude of such interactions has not been defined. To the extent that this figure fails to account for these interactions between outcomes, the attrition in optimal reperfusion is exaggerated. The adverse effects of critical residual stenosis, relatively late administration ofthrombolytic therapy, and reperfusion injury are not included in this diagram as well; to the extent that these factors limit effective reperfusion, this figure underestimates the attenuation of thrombolytic benefit. tion, only three-fourths will have complete patency as defined by the presence of TIMI 3 rather than TIMI 2 grade coronary flow; moreover, severe residual stenoses will be present in a variable number of these patients (the adverse influence of residual coronary narrowing was not included in Figure 3 due to uncertainties regarding the level of stenosis that is proper for dichotomization and the extent of interaction between stenosis and TIMI grade). Even with restoration of normal epicardial coronary blood flow, reperfusion at the myocardial tissue level may fail to occur in 20% or more of patients. Finally, the phenomena of intermittent patency in one third of patients after thrombolytic recanalization and reocclusion in 10-15% of those treated with t-PA will further diminish the proportion of patients in whom reperfusion can be considered optimal. Integration of these data, as outlined in Figure 3 , suggests that current thrombolytic therapy is effective in producing optimal reperfusion in 25% or less of patients treated for acute myocardial infarction.
The magnitude of clinical benefit presently derived from thrombolytic therapy for acute infarction is consistent with the premise that only a minority of patients actually achieve optimal reperfusion. Mortality among treated patients remains substantial; among more than 50,000 patients receiving thrombolytic agents during the contemporary period of [1988] [1989] [1990] [1991] in the GISSI-212 or ISIS-313 trials, the 35-day mortality rate was 10.1%. Reinfarction continues to occur in 3-4%, and congestive heart failure occurs in 10-15% of patients. Furthermore, except among patients in whom thrombolytic therapy is initiated very early in the course of infarction, salvage of left ventricular function has been only modest, with improvements in ejection fraction averaging only 2-3% with thrombolytic rather than placebo therapy. It therefore seems unlikely that clinical outcome after acute myocardial infarction can be further enhanced in any real manner without substantial improvements in the quality of reperfusion for the majority of treated patients.
Emerging Strategies Toward More Optimal Reperfusion
Recently developed techniques to critically assess the quality of reperfusion in patients with acute infarction, coupled with the introduction of novel pharmacological agents and an improved understanding of the roles and mechanisms of existing thrombolytic and adjunctive drugs, have provided the opportunity to overcome many of the present limitations of reperfusion therapy. Progress may be made in each of three major fronts in the pursuit of optimal reperfusion: 1) enhancement of thrombolysis to rapidly attain brisk, true, and sustained reperfusion; 2) reduction in the incidence and severity of adverse effects of thrombolysis; and 3) use of alternative pathways to achieve myocardial salvage.
Enhanced Thrombolysis
Among the most important accomplishments in the development of reperfusion therapy has been recognition of the profound benefit of very early administration of thrombolytic agents. As illustrated in Figure 1 , several studies have demonstrated that mortality may be reduced by more than 50% during the golden first hour after symptom onset,1,2,57-59 whereas mortality advantage drops sharply thereafter to a virtual plateau for the remainder of the 6-12-hour window of proven benefit. It appears, in fact, that very early initiation of therapy results in a more marked improvement in clinical outcome than all other modifications of thrombolytic regimens or .adjunctive interventions combined. However, only a small minority of patients with acute infarction actually receive very early therapy. During the GISSI-1, GISSI-2, and ISIS-2 experiences with more than 40,000 patients between 1984 and 1989,1,2,12 only 10.8% were treated within 1 hour of symptom onset; even more disappointing is that only 3% of 14,000 patients entered into the ongoing Global Utilization of Streptokinase or t-PA for Occluded Coronary Arteries (GUSTO) trial have been treated within 60 minutes. Although a component of the time delay between symptom onset and administration of thrombolytic therapy may be unavoidable, the currently dismal performance record in this regard may be improved by enhanced efforts toward public education and rapid triage of patients presenting with chest pain to prompt initiation of reperfusion therapy (including prehospital thrombolysis in some settings).57 '59 Currently under investigation are several approaches to improving the efficacy of reperfusion therapy through optimization of dosing, timing, or selection of thrombolytic agents. The patency standard by which new regimens are assessed now is the accelerated administration of t-PA, originally proposed by Neuhaus et al,10'39 with or without adjustment of dosage for weight.43 Although further intensification of "front-loaded" thrombolytic dosing has been examined by the TAMI study group, rates of infarct artery patency obtained by more rapid infusion of t-PA actually were lower than those with the Neuhaus et al regimen.43 Increase of total t-PA dose beyond 100 mg has led to an excessive incidence of intracranial hemorrhage (2.1-2.4%) in other studies.'6,42 It thus appears that the ceiling of rapid acute patency with t-PA monotherapy may have been reached, with additional increments in recanalization rates achieved only at the expense of substantially greater risk of serious hemorrhagic complications. More encouraging preliminary data have associated a reduced incidence of reocclusion with the combination of fibrinselective and -nonselective thrombolytic agents,34'38'43'87 although the speed or extent of acute arterial recanalization does not appear to be influenced by combination therapy. The large-scale randomized GUSTO trial is examining the clinical impact of accelerated and combined thrombolytic regimens.
Novel plasminogen activators have been developed that appear to exhibit increased fibrin affinity, fibrin specificity, or serum half-lives. Recombinant plasminogen activator (r-PA), a t-PA deletion mutant with enhanced fibrinolytic activity and extended half-life, has been initially evaluated in 143 patients in the GRECO study,89 with very early 30-minute patency rates ranging from 66% to 73% in the preliminary report of this dose-escalation trial. Vampire bat salivary plasminogen activator (bat-PA) exhibits increased fibrin selectivity and potency by virtue of its requirement for fibrin as a cofactor, potentially leading to improved thrombolytic activity without increased bleeding risk. 90 A number of new platelet antagonists have been developed as potential adjuncts to thrombolytic reperfusion. A growing body of evidence, summarized in a recent review by Coller, 91 suggests that platelets exert a major adverse influence on the efficacy of thrombolytic therapy by increasing the resistance of clot to fibrinolysis, delaying reperfusion, and facilitating cyclical flow and reocclusion. In animal models, cyclical flow variations and reocclusion after thrombolysis can be abolished by thromboxane A2 antagonists.71 Aspirin, an inhibitor of thromboxane A2 production via cyclo-oxygenase blockade, was shown in the ISIS-2 trial to substantially diminish mortality and reinfarction rates in patients with acute myocardial infarction, an effect that was additive to that of streptokinase.2 Multiple mechanisms of platelet activation that are independent of the thromboxane pathway exist, however, thus limiting the effectiveness of thromboxane antagonism by aspirin or other drugs in preventing rethrombosis. 92 The most promising new antiplatelet agents under investigation are those directed against the GPIIb/IIIa receptor, the final common pathway leading to platelet aggregation. Blockade of this membrane receptor by the potent monoclonal antibody 7E3 has been shown to accelerate coronary artery recanalization with t-PA, prevent reocclusion, and decrease infarct size in animal models.93'94 Murine 7E3 administered with t-PA was well tolerated while producing profound platelet inhibition in a preliminary report of a dose-escalation trial of 60 patients with acute myocardial infarction95; chimeric 7E3 also has been safely used during a pilot study in patients undergoing elective coronary angioplasty. Several other antagonists of the GPIIb/IIIa receptor, which competitively bind the common recognition site to the tripeptide sequence arginine-glycine-aspartate, also have been isolated or synthesized; as with the 7E3 antibody, these antagonists have been demonstrated in animal studies to effectively increase the speed of coronary thrombolysis and limit reocclusion.96'97 Integrelin and MK-852, oligopeptide GPIIb/IIIa inhibitors of this class, are under clinical investigation in patients with unstable angina.
Adjunctive therapy with thrombin inhibitors may attenuate thrombin-mediated platelet activation and recurrent thrombosis during fibrinolytic therapy.72'74'98 Heparin diminishes the incidence of reocclusion when administered in high doses after thrombolysis with t-PA,84-86 but it has been ineffective in accelerating or enhancing acute infarct artery patency.37 The anticoagulant potency of this thrombin inhibitor appears to be modest, due in part to the dependence of heparin on antithrombin-III and its inability to act on thrombin bound to fibrin clot.83 Hirudin, a peptide derived from the saliva of medicinal leeches that selectively binds to the fibrinogen recognition and catalytic sites of thrombin, holds promise as a powerful adjunct to thrombolysis. In experimental animal studies, recombinant hirudin is more active than heparin in preventing thrombus formation, inhibiting clot-bound and circulating thrombin, and blocking platelet activation.99100 Adjunctive treatment of acute myocardial infarction with hirudin is under evaluation in the ongoing TIMI V and VI trials. Other synthetic thrombin inhibitors have been shown in early animal experiments to be effective in diminishing vascular thrombosis, including PPACK,101 an irreversible catalytic site alkylator, and argatroban, a competitive antagonist.102 In addition, selective inhibition of factor Xa, a central component of both the intrinsic and extrinsic coagulation cascades, has resulted in dramatic acceleration of thrombolytic reperfusion and prevention of reocclusion in an animal model. 92 The key role played by both platelets and thrombin in antagonizing the action of fibrinolytic drugs provides rationale for combination adjunctive therapy with antiplatelet and antithrombin agents. The incremental value of heparin added to thrombolytic and aspirin therapy was examined in the GISSI-2 and ISIS-3 randomized trials,12'13 with no significant difference in 35-day mortality observed after heparin treatment. Extrapolation of these results is limited, however, by the predominantly subcutaneous route of heparin administration and lack of anticoagulation monitoring used in these studies; infarct artery patency, particularly with t-PA, has been correlated with the intensity of heparin anticoagulation.103 The 14, 15, 17 Similarly, a strategy of routine PTCA on the first or second day after thrombolysis has been shown to be inferior to one of deferred PTCA or "watchful waiting." '6,106 Performance of angioplasty to restore coronary patency in the setting of failed reperfusion, however, commonly is performed, and a randomized controlled study to evaluate the efficacy of this "rescue" strategy is under way.107 Moreover, early (within 90 minutes) percutaneous revascularization for recurrent ischemia after successful thrombolysis has been demonstrated to diminish in-hospital mortality in a retrospective analysis. 108 The role of coronary angioplasty in patients with incomplete (TIMI 2) reperfusion or intermittent patency has not been examined.
Selective application of coronary angioplasty or other adjunctive strategies to patients with suboptimal reperfusion after thrombolysis will be critically dependent on the ability to rapidly and noninvasively assess the adequacy of myocardial perfusion. During a prospective study of 144 patients treated with thrombolytic therapy,109 the status of infarct artery patency was predicted correctly using continuous 12-lead ST segment recovery analysis in all except 20 patients; notably, TIMI 2 flow or collateralized occlusions were present in 13 of the 20 patients in whom predicted patency was incorrect in this preliminary report. Encouraging results by these and other investigators77,78 suggest that continuous ECG ST segment monitoring may prove to be a reliable real-time technique of identifying infarct artery patency and allow specific therapies to be targeted to patients who have not achieved optimal reperfusion.
Modification ofAdverse Effects of Thrombolysis: The Early Hazard
Mortality data derived from several large, placebocontrolled trials of thrombolytic therapy have demonstrated the phenomenon of "early hazard." During the first 24 hours after therapy, patients receiving thrombolytic agents are at higher risk for death than are placebo-treated controls (Figure 4) ,52,110 although subsequent survival benefit from thrombolytic treatment translates into an overall net improvement in mortality. Importantly, a collaborative analysis of seven major randomized, controlled thrombolytic trials suggested that the early hazard may not be present in patients receiving thrombolytic therapy within 3 hours of symptom onset, whereas a progressive increase in the magnitude of early hazard was linked to increasing intervals between symptom onset and treatment thereafter; in contrast, subsequent (day 2 and later) benefit derived from thrombolysis was not a function of time to treatment."' This finding clearly implicates the early hazard as a critical determinant of the diminished net mortality benefit among patients in whom thrombolytic therapy is initiated more than 1-2 hours after onset of infarction (Figure 1) . Thus, interventions aimed at amelioration of the early hazard may substantially diminish the overall mortality associated with myocardial infarction.
It remains unclear why thrombolysis produces a deleterious effect on clinical outcome during the first 24 hours; bleeding complications, for example, do not appear responsible, as predominant causes of mortality in these patients include heart failure, electromechani-cal dissociation, and ventricular rupture.110'112 The potential role of cardiac tamponade early after thrombolysis, as reported by Renkin et al, deserves further study.'13 It is possible, although speculative, that myocardial hemorrhage or extension of myocardial necrosis induced by reperfusion injury plays a role in the pathogenesis of early hazard.1"4 In addition, recurrent ischemia due to early reocclusion or intermittent patency may, in the setting of reperfusion injury after successful thrombolysis, produce a degree of myocardial necrosis equal to that caused by complete failure of infarct vessel recanalization. Although microvascular injury and endothelial dysfunction have been demonstrated in animal models of ischemia and reperfusion, leading to the no-reflow phenomenon, myocardial hemorrhage, and diminished myocardial salvage,"-5-"18 the clinical importance of reperfusion injury after thrombolysis remains controversial. In experimental models, superoxide dismutase and catalase,'19 N-acetylcysteine,'19 adenosine,'20 and perfluorochemicals12' have limited reperfusion injury through neutralization of oxygen free radicals or inhibition of neutrophil function, but benefit in humans has yet to be shown with these agents. During a randomized controlled trial in which superoxide dismutase was administered intravenously to patients undergoing primary or rescue coronary angioplasty for acute myocardial infarction, treatment with superoxide dismutase offered no benefit over placebo with regard to improvement in ventricular function, although the incidence of reperfusion arrhythmias was reduced. ' "open vessel" hypothesis that prognosis is improved by restoration of infarct artery patency has not and cannot truly be tested until optimal reperfusion becomes a practical reality.
An appreciation of the limitations of current thrombolytic strategies, coupled with the development of novel pharmacological agents and of new techniques for assessing the adequacy of myocardial perfusion, has created a window of opportunity to enhance the quality of reperfusion therapy for acute myocardial infarction. Although various combinations of thrombolytic and adjunctive agents may be targeted to the specific barriers to optimal reperfusion, the pathogenesis and causeand-effect relations among poor myocardial salvage and the phenomena of intermittent patency, TIMI 2 flow, and no-reflow also must be explored. Rather than complacency with current treatment regimens and approaches, expectations for clinical benefit from reperfusion therapy should be upgraded. By the end of this second decade of thrombolytic therapy, mortality for eligible patients with acute myocardial infarction may once again be halved if the inadequacies of present methodologies can be surmounted. 
